> Patients must spend weeks, even months, in the hospital before and after the therapy is administered.
Yoiks. So how many actual people are going to be able to get this treatment?
21–30 of 228 posts
> Patients must spend weeks, even months, in the hospital before and after the therapy is administered.
Yoiks. So how many actual people are going to be able to get this treatment?
Earlier quoted context omitted.
[flagged]
What genes do you think we should be testing for and which ones do you think are severe enough that you parents with those genes shouldn't have children? Almost everyone has some sort of gene that isn't great. They might have a family history of Alzheimer's, maybe a family history or some sort of cancer, or bipolar disorder, or any other of 100 different serious illnesses. Humans would go extinct if we only allowed t…
[flagged]
If you're interested in this, check out Bryan Johnson and Blueprint.
> Ohalo had two RSRs under consideration this year for its potato, one which focuses on higher concentrations of beta carotene – enhancing the overall health and nutrition value of the potato – and another which results in reduced glucose and fructose content in the potato, which, according to Ohalo, will reduce the adverse side effects that lead to significant spoilage during cold storage of potatoes.
https://thespoon.tech/gene-edited-food-startup-ohalo-emerges...
> Vertex set the price of Casgevy at $2.2 million > Patients must spend weeks, even months, in the hospital before and after the therapy is administered. Yoiks. So how many actual people are going to be able to get this treatment?
"""Each treatment is an individualized “one-off” treatment. For this reason, a single treatment for a single patient is expensive. At present it is estimated that in the UK treatment will cost £1 million or more. In the US the estimated cost is $2 million.
That may seem prohibitive, but we need to consider the overall cost-effectiveness of the treatment, which means comparing the cost of treatment to the cost of managing each disease without the treatment. Sickle cell patient require frequent hospitalization, which can be very expensive. One analysis found that Casgevy can be cost effective at £1.5 million or $1.9 million. This is in range of the estimated cost. Also, the longer the treatment benefits last, the more cost effective the treatment becomes. A lifetime of transfusions or hospital admissions adds up."""
https://sciencebasedmedicine.org/first-crispr-treatment-appr...
Earlier quoted context omitted.
You're going to want to avoid using language straight out of GATTACA if you want to have a real conversation on this topic.
We voluntarily did DNA tests on both of us to rule out any parental defects, as well as tests in utero to see if there were issues. Luckily there were none, but we had some discussions on what we might do. It seems reasonable and responsible to perform these tests to be informed on your major life choices.
If you don't mind sharing, what was the (rough) cost to you for the testing?
> Vertex set the price of Casgevy at $2.2 million > Patients must spend weeks, even months, in the hospital before and after the therapy is administered. Yoiks. So how many actual people are going to be able to get this treatment?
More info I found relevant regarding cost for typical treatment and out of pocket estimated costs: https://www.hematology.org/newsroom/press-releases/2022/the-...
Earlier quoted context omitted.
If you're interested in this, check out Bryan Johnson and Blueprint.
Why anyone would be interested by a charlatan?